#PrimaryEndpoint
LightNews LightNews
onco404.bsky.social
The phase 3 #IMPower151 trial evaluated atezolizumab + bevacizumab + CT (ABCPem/Pac) vs bevacizumab + CT (BCPem/Pac) in 305 Chinese pts with metastatic nsqNSCLC

#NatureMedicine @natureportfolio.nature.com

#Onco404 #Cancer #Kanser #LungCancer #Immunotherapy #ClinicalTrials #PrimaryEndpoint #MedSky
May 20, 2025 at 3:34 PM
4040rec.bsky.social
#oncology #Lilly #LillyOncology #Jaypirca #Pirtobrutinib #primaryendpoint #EliLilly #CLL313 #CLL314 #phase3 #BRUINCLL314trial #chroniclymphocyticleukaemia #CLL #smalllymphocyticlymphoma #SLL #noncovalentBTKinhibitor #Imbruvica #ibrutinib #covalentBTKinhibitor
pharmatimes.com/news/lillys-...
Lilly’s Jaypirca shows positive results in phase 3 trial - PharmaTimes
Pirtobrutinib meets primary endpoint in CLL/SLL study
pharmatimes.com
September 9, 2025 at 10:14 AM
4040rec.bsky.social
#UCB #bimekizumab #psoriaticarthritis #PsA #PsAbiologic #BEBOLDtrial #risankizumab #activepsoriaticarthritis #EULAR #biologics #headtoheadtrials #primaryendpoint #ACR50 #secondaryendpoints #diseaseactivity #inflammationcontrol #qualityoflife #headtoheadtrialdesign
zurl.co/htasR
UCB reports positive outcomes for bimekizumab in psoriatic arthritis - PharmaTimes
Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic
pharmatimes.com
May 20, 2026 at 8:45 AM
4040rec.bsky.social
#PierreFabre #ECapproval #Braftovi #encorafenib #colorectalcancer #BRAFV600EmutantmCRC #metastaticcolorectalcancer #mCRC #combinationtherapy #cetuximab #FOLFOX #phase3 #Breakwatertrial #progressionfreesurvival #primaryendpoint #overallsurvivalbenefit #LaboratoiresPierreFabre
zurl.co/7jFHW
Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC - PharmaTimes
Breakwater phase 3 data show significant gains in progression‑free survival
pharmatimes.com
June 24, 2026 at 8:48 AM
4040rec.bsky.social
#nephrology #Xeltis #aXesstrialresults #aXessclinicaltrial #phase3trial #restorativevascularaccess #vascularaccess #haemodialyisis #primaryendpoint #endstagerenaldisease #haemodiaylisisvascularaccesstreatment #EndogenousTissueRestorationplatform #vascularaccess #dialysispatients
zurl.co/UPkoj
Xeltis prepares for commercial launch after strong aXess trial results - PharmaTimes
EU phase 3 data shows major gains in dialysis access performance
pharmatimes.com
September 25, 2025 at 11:28 AM
4040rec.bsky.social
#Amgen #KyowaKirin #rocatinlimab #atopicdermatitis #phase3study #ASCENDstudy #Tcellrebalancingtherapy #OX40receptor #drugsafety #efficacy #ROCKETtrial #primaryendpoint #secondaryendpoints #HORIZONtrial #IGNITEtrial #rocatinlimabmonotherapy #OX40inhibition
pmlive.com/pharma_news/...
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis - PMLiVE
The phase 3 study included around 2,600 patients
pmlive.com
September 23, 2025 at 8:23 AM
4040rec.bsky.social
#painmanagement #healthcare #pain #TrisPharma #ALLEVIATE1clinicaltrial #cebranopadol #Phase3trial #painrelief #acutepain #abdominoplasty #primaryendpoint #reducingpainintensity #Painintensity #NRSscale #analgesia #opioids #painmanagement #NDAsubmission
pharmatimes.com/news/tris-ph...
Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol - PharmaTimes
Phase 3 trial shows promising pain relief for acute pain patients
pharmatimes.com
January 28, 2025 at 12:30 PM